NKGen Biotech, Inc. (NYSE:NKGN) Shares Sold by Polar Asset Management Partners Inc.

Polar Asset Management Partners Inc. decreased its stake in NKGen Biotech, Inc. (NYSE:NKGN) by 57.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 500,000 shares of the company’s stock after selling 681,872 shares during the quarter. Polar Asset Management Partners Inc. owned approximately 1.11% of NKGen Biotech worth $328,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Geode Capital Management LLC increased its position in shares of NKGen Biotech by 12.8% in the fourth quarter. Geode Capital Management LLC now owns 127,168 shares of the company’s stock valued at $83,000 after buying an additional 14,454 shares in the last quarter. Advisory Research Inc. purchased a new stake in NKGen Biotech in the 4th quarter worth $28,000. Sequoia Financial Advisors LLC raised its position in NKGen Biotech by 126.1% during the fourth quarter. Sequoia Financial Advisors LLC now owns 156,000 shares of the company’s stock worth $102,000 after acquiring an additional 87,000 shares during the period. Kepos Capital LP purchased a new position in NKGen Biotech during the fourth quarter valued at $151,000. Finally, Magnetar Financial LLC purchased a new position in NKGen Biotech during the fourth quarter valued at $175,000. 76.17% of the stock is owned by institutional investors and hedge funds.

NKGen Biotech Stock Up 6.8%

NKGN stock opened at $0.35 on Friday. NKGen Biotech, Inc. has a 52 week low of $0.10 and a 52 week high of $2.19. The firm has a 50-day simple moving average of $0.17 and a 200-day simple moving average of $0.36. The stock has a market capitalization of $15.72 million, a P/E ratio of -0.07 and a beta of 0.84.

About NKGen Biotech

NKGen Biotech, Inc operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials.